Arcus Biosciences (RCUS) News Today → Does this make you sick? (From Allegiance Gold) (Ad) Free RCUS Stock Alerts $16.90 -0.56 (-3.21%) (As of 05/17/2024 08:54 PM ET) Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative May 19 at 9:00 AM | marketbeat.comArcus Biosciences, Inc. (NYSE:RCUS) Shares Bought by Panagora Asset Management Inc.Panagora Asset Management Inc. increased its position in Arcus Biosciences, Inc. (NYSE:RCUS - Free Report) by 130.6% during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 228,996 shares of the company's stMay 16, 2024 | americanbankingnews.comArcus Biosciences, Inc. (NYSE:RCUS) Receives Average Recommendation of "Moderate Buy" from BrokeragesMay 16, 2024 | marketbeat.comArcus Biosciences, Inc. (NYSE:RCUS) Given Average Recommendation of "Moderate Buy" by AnalystsShares of Arcus Biosciences, Inc. (NYSE:RCUS - Get Free Report) have been assigned an average recommendation of "Moderate Buy" from the eight research firms that are covering the firm, Marketbeat reports. One equities research analyst has rated the stock with a hold rating and seven have issued aMay 15, 2024 | markets.businessinsider.comBuy Rating on Arcus Biosciences: Unique Anti-TIGIT Antibody and Promising Cancer Trials Fuel OptimismMay 15, 2024 | seekingalpha.comArcus Biosciences: A Preview Of Their Outlook Ahead Of ASCOMay 14, 2024 | markets.businessinsider.comOptimistic Buy Rating for Arcus Biosciences Based on Promising Efficacy and Safety Profile of DomvanalimabMay 13, 2024 | americanbankingnews.comWedbush Reiterates "Outperform" Rating for Arcus Biosciences (NYSE:RCUS)May 13, 2024 | americanbankingnews.comQ2 2024 Earnings Estimate for Arcus Biosciences, Inc. Issued By Wedbush (NYSE:RCUS)May 12, 2024 | finance.yahoo.comArcus Biosciences, Inc. (NYSE:RCUS) Reported Earnings Last Week And Analysts Are Already Upgrading Their EstimatesMay 12, 2024 | americanbankingnews.comArcus Biosciences (NYSE:RCUS) Trading Up 9.3%May 11, 2024 | americanbankingnews.comWedbush Weighs in on Arcus Biosciences, Inc.'s Q1 2025 Earnings (NYSE:RCUS)May 10, 2024 | marketbeat.comArcus Biosciences (NYSE:RCUS) Trading 9.3% Higher Arcus Biosciences (NYSE:RCUS) Stock Price Up 9.3%May 10, 2024 | finance.yahoo.comArcus Biosciences Surpasses Analyst Revenue Forecasts in Q1 2024May 10, 2024 | finance.yahoo.comArcus Biosciences First Quarter 2024 Earnings: Beats ExpectationsMay 10, 2024 | marketbeat.comBrokers Set Expectations for Arcus Biosciences, Inc.'s Q1 2025 Earnings (NYSE:RCUS)Arcus Biosciences, Inc. (NYSE:RCUS - Free Report) - Research analysts at Wedbush issued their Q1 2025 earnings estimates for shares of Arcus Biosciences in a research report issued on Wednesday, May 8th. Wedbush analyst R. Driscoll anticipates that the company will earn ($0.80) per share for theMay 10, 2024 | americanbankingnews.comArcus Biosciences (NYSE:RCUS) Shares Gap Up Following Strong EarningsMay 9, 2024 | markets.businessinsider.comWedbush Reaffirms Their Buy Rating on Arcus Biosciences (RCUS)May 9, 2024 | businesswire.comArcus Biosciences Announces New Employment Inducement GrantsMay 9, 2024 | finance.yahoo.comArcus Biosciences, Inc. (NYSE:RCUS) Q1 2024 Earnings Call TranscriptMay 9, 2024 | marketbeat.comArcus Biosciences (NYSE:RCUS) Announces Earnings Results, Beats Estimates By $0.92 EPSArcus Biosciences (NYSE:RCUS - Get Free Report) released its quarterly earnings results on Wednesday. The company reported ($0.05) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.97) by $0.92. Arcus Biosciences had a negative net margin of 262.39% and a negative return on equity of 57.17%. The company had revenue of $145.00 million for the quarter, compared to analysts' expectations of $28.77 million. During the same period last year, the company earned ($1.09) EPS. The firm's revenue for the quarter was up 480.0% compared to the same quarter last year.May 9, 2024 | markets.businessinsider.comArcus Biosciences: Holding Steady Amidst Progress and UncertaintiesMay 9, 2024 | marketbeat.comArcus Biosciences (NYSE:RCUS) Shares Gap Up on Strong EarningsArcus Biosciences (NYSE:RCUS) Shares Gap Up Following Earnings BeatMay 9, 2024 | marketbeat.comArcus Biosciences (NYSE:RCUS) Receives "Outperform" Rating from WedbushWedbush reissued an "outperform" rating and set a $30.00 price target on shares of Arcus Biosciences in a research report on Thursday.May 9, 2024 | finance.yahoo.comArcus Biosciences Inc (RCUS) Q1 2024 Earnings Call Transcript Highlights: Strategic ...May 8, 2024 | investorplace.comRCUS Stock Earnings: Arcus Biosciences Beats EPS, Beats Revenue for Q1 2024May 8, 2024 | finance.yahoo.comArcus Biosciences Reports First-Quarter 2024 Financial Results and Provides a Pipeline UpdateMay 7, 2024 | marketwatch.comPrecision BioSciences Gets FDA Fast Track Designation for Program to Treat Genetic Urea Cycle Disorder in NewbornsMay 2, 2024 | businesswire.comArcus Biosciences to Participate in the Bank of America Healthcare Conference 2024May 2, 2024 | markets.businessinsider.comPromising Outlook for Arcus Biosciences Anchored by Strong Clinical Trials and Strategic Market PositioningMay 1, 2024 | marketbeat.comArcus Biosciences (RCUS) to Release Quarterly Earnings on WednesdayArcus Biosciences (NYSE:RCUS) will be releasing earnings after the market closes on Wednesday, May 8, Zacks reports. (Register for Conference Call at http://mmm.wallstreethorizon.com/u.asp?u=588036)April 28, 2024 | marketbeat.comArcus Biosciences, Inc. (NYSE:RCUS) Short Interest Down 17.1% in AprilArcus Biosciences, Inc. (NYSE:RCUS - Get Free Report) saw a large decrease in short interest in April. As of April 15th, there was short interest totalling 6,840,000 shares, a decrease of 17.1% from the March 31st total of 8,250,000 shares. Currently, 14.5% of the company's stock are short sold. Based on an average daily volume of 819,200 shares, the short-interest ratio is presently 8.3 days.April 24, 2024 | businesswire.comArcus Biosciences to Present New Data from Phase 2 Studies of Novel Immuno-Oncology Combinations at the 2024 ASCO Annual MeetingApril 23, 2024 | businesswire.comArcus Biosciences to Host Conference Call to Discuss First-Quarter 2024 Financial Results and Pipeline UpdateApril 18, 2024 | bizjournals.comEli Lilly subsidiary ends lucrative collaboration with Durham biotechApril 18, 2024 | markets.businessinsider.comPrecision BioSciences: Strategic Independence and Promising Gene Editing Pipeline Fuel Buy RatingApril 17, 2024 | markets.businessinsider.comBuy Rating Affirmed for Precision BioSciences Amid Strong Gene Editing Prospects and Upcoming MilestonesApril 9, 2024 | businesswire.comArcus Biosciences Announces New Employment Inducement GrantsApril 6, 2024 | marketbeat.comVanguard Group Inc. Acquires 61,040 Shares of Arcus Biosciences, Inc. (NYSE:RCUS)Vanguard Group Inc. increased its holdings in shares of Arcus Biosciences, Inc. (NYSE:RCUS - Free Report) by 1.4% during the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 4,493,818 shares ofApril 3, 2024 | marketbeat.comArcus Biosciences (NYSE:RCUS) Shares Down 2.8% Arcus Biosciences (NYSE:RCUS) Trading Down 2.8%April 1, 2024 | finance.yahoo.comInvestors bid Arcus Biosciences (NYSE:RCUS) up US$219m despite increasing losses YoY, taking five-year CAGR to 8.1%March 30, 2024 | insidertrades.comInsider Selling: Arcus Biosciences, Inc. (NYSE:RCUS) COO Sells 11,551 Shares of StockMarch 29, 2024 | finance.yahoo.comInsider Sell: COO Jennifer Jarrett Sells 11,551 Shares of Arcus Biosciences Inc (RCUS)March 29, 2024 | marketbeat.comArcus Biosciences, Inc. (NYSE:RCUS) COO Jennifer Jarrett Sells 11,551 SharesArcus Biosciences, Inc. (NYSE:RCUS - Get Free Report) COO Jennifer Jarrett sold 11,551 shares of the firm's stock in a transaction dated Wednesday, March 27th. The shares were sold at an average price of $17.55, for a total value of $202,720.05. Following the completion of the sale, the chief operating officer now directly owns 215,253 shares in the company, valued at $3,777,690.15. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink.March 29, 2024 | msn.comXilio and Gilead partner up for IL-12 therapeutic developmentMarch 27, 2024 | marketbeat.comArcus Biosciences (NYSE:RCUS) Trading Up 7.6%Arcus Biosciences (NYSE:RCUS) Shares Up 7.6%March 26, 2024 | businesswire.comArcus Biosciences Announces New Employment Inducement GrantsMarch 25, 2024 | markets.businessinsider.comNavigating 5 Analyst Ratings For Arcus BiosciencesMarch 25, 2024 | marketbeat.comTruist Financial Reiterates Buy Rating for Arcus Biosciences (NYSE:RCUS)Truist Financial reaffirmed a "buy" rating and set a $50.00 target price on shares of Arcus Biosciences in a research note on Monday.March 22, 2024 | investing.comArcus Biosciences COO sells over $240k in company stockMarch 21, 2024 | insidertrades.comInsider Selling: Arcus Biosciences, Inc. (NYSE:RCUS) COO Sells 13,449 Shares of Stock Get Arcus Biosciences News Delivered to You Automatically Sign up to receive the latest news and ratings for RCUS and its competitors with MarketBeat's FREE daily newsletter. Email Address This Apple-like Innovator is Revolutionizing Healthcare (Ad)AI has infiltrated so many sectors, it's sent the demand for AI-friendly GPU computer chips rocketing. Nvidia has gone up more than 3x in the past year. It is now valued well over $2 trillion, making it one of the largest companies in the world. Click here to learn more about the booming eHealth industry RCUS Media Mentions By Week RCUS Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. RCUS News Sentiment▼0.340.42▲Average Medical News Sentiment RCUS News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. RCUS Articles This Week▼84▲RCUS Articles Average Week Get Arcus Biosciences News Delivered to You Automatically Sign up to receive the latest news and ratings for RCUS and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: ANI Pharmaceuticals News Today Kiniksa Pharmaceuticals News Today Day One Biopharmaceuticals News Today Xencor News Today Morphic News Today Protagonist Therapeutics News Today Akero Therapeutics News Today Gemini Therapeutics News Today Ligand Pharmaceuticals News Today Dynavax Technologies News Today Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NYSE:RCUS) was last updated on 5/20/2024 by MarketBeat.com Staff From Our PartnersRed Alert: Your Money's Disappearance Act - Banks' Greed Unleashed!Priority GoldDoes this make you sick?Allegiance GoldUrgent Nvidia WarningAltimetryThe Overlooked Retirement Asset You Probably Don’t OwnCrypto 101 MediaThis Apple-like Innovator is Revolutionizing HealthcareWall Street StarShocking: One AI startup's revenue could surge 4,735%Manward PressGlobal crypto currency reset (41 major banks signed up)Stansberry ResearchExposed: 10 CENT Crypto to Explode May 20th?True Market Insiders Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Arcus Biosciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
